Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from his duties pending an inquiry, officials said on Friday. The boy, identified by his first name, Adeeb, a resident of Sambhal, was bitten by a snake on Monday while playing in the courtyard of his house. He had put his hand into a hole in a wall to retrieve a marble when the snake struck him, his family said. The boy was taken to the district hospital, where staff allegedly...

The court left the food regulator free to pass a fresh order after issuing a show-cause notice to the company and giving it a hearing.New Delhi: The Delhi High Court has quashed an order of the Food Safety and Standards Authority of India (FSSAI) that had directed Red Bull India to stop using the word "energy" for its drinks, finding that the company had been denied natural justice, according to ETHealthworld.Justice Amit Mahajan allowed Red Bull India's petition on that limited ground. The company had argued that the regulator issued its order without first serving a show-cause notice or giving...

Chief Minister Nayab Singh Saini also set a 1 November deadline for opening Amrit Pharmacies in every government hospital in the state.Chandigarh: Government hospitals in Haryana will be allowed to spend the money they receive for treating patients under the Ayushman Bharat and Chirayu schemes on special incentives for doctors and staff, upgradation, sanitation work and Ayushman Mitras, Chief Minister Nayab Singh Saini announced on Tuesday. The state government has approved a proposal submitted by the Health Department to this effect, according to The Tribune.Saini made the announcement while chairing a review meeting with Health Department officials at the Haryana...

Generic medicines and their ingredients remain outside the Section 232 pharmaceutical tariffs, according to the US Commerce Department notice.New Delhi: India is among 20 jurisdictions whose qualifying speciality medicines will enter the United States at zero duty, even as a 100 per cent tariff on specified patented pharmaceutical products was extended to more companies from 29 September, according to a notice from the US Department of Commerce.The department's Bureau of Industry and Security listed the eligible jurisdictions in a notice published in the Federal Register on 23 September. The zero rate applies to rare-disease drugs whose approved uses all carry...

An AIIMS New Delhi doctor sat on the 23-member expert group, and eligible Indians can seek screening through the Indian Lung Screening Trial he leads. New Delhi: Screening with low-dose computed tomography can reduce the risk of dying from lung cancer by 16 per cent among high-risk people and also lower the number of cases found at stage III or IV, a working group of the International Agency for Research on Cancer (IARC) has concluded in an assessment published in The New England Journal of Medicine. The IARC panel of 23 clinicians and scientists from 17 countries, including Dr Abhishek...

The company said the assets are freehold and unencumbered, so the sale will not touch the security package given to its lenders. Mumbai: Krsnaa Diagnostics said its board has approved the sale of identified diagnostic equipment to identified purchasers for an aggregate consideration of up to Rs 120 crore, as the diagnostics provider moves towards a lighter asset base. According to the company, the proposed sale is part of an ongoing strategic exercise aimed at optimising its asset portfolio and improving capital efficiency. Krsnaa said it had built up a substantial base of assets over the years to support the...

The chain will pay a further Rs 31.5 crore if SN Genelab meets agreed performance targets, on top of Rs 168 crore for a 70 per cent stake. New Delhi: Dr Lal PathLabs' purchase of a majority stake in SN Genelab adds a specialised genomics laboratory to its business, but the target is too small to lift the diagnostic chain's earnings in the short run, according to an analysis published by Mint. SN Genelab reported revenue of Rs 58 crore in FY26, roughly 2 per cent of what Dr Lal PathLabs earned last year, the report said. It cited Nomura...

Of the candidates considered in the first round, 14,736 were allotted their first-choice college and must accept the seat, the state CET Cell said.Mumbai: The Maharashtra State Common Entrance Test Cell has published the first Centralized Admission Process (CAP) list for first-year B.Pharmacy and Pharm.D courses for 2026-27, offering admission to 28,139 students across 528 pharmacy colleges in the state, according to The Times of India.The participating colleges together have 46,984 seats on offer, the CET Cell said. Of the 44,329 candidates who registered for admission, 35,988 filed their college preferences within the stipulated window and were considered in the...

Pending applications to raise intake in existing postgraduate courses or to start new ones are not part of the list and will be added only once approved, the commission said.New Delhi: The Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) on Tuesday published the postgraduate (PG) medical seat matrix for the 2026-27 academic year, setting out the approved annual intake that will go into NEET PG 2026 counselling, according to The Indian Express.The matrix names each medical college and institution, the PG courses it runs and the intake capacity cleared by MARB, the commission said in...

A final decision on switching the medical entrance test to computers will follow only after the Nandan Nilekani-led task force on examination reforms submits its recommendations, officials said.New Delhi: The Union Ministry of Education is drawing up a national strategy for computer-based testing (CBT) infrastructure that could allow the National Eligibility-cum-Entrance Test for undergraduate medical admissions (NEET-UG) to move away from pen and paper, officials told The Indian Express.The plan seeks to create examination-grade capacity for large national entrance tests by adding test centres, setting common infrastructure specifications and allowing more offline exams to shift to computers, according to the...

The mining company has put Rs 1 crore into the new subsidiary, which will make, assemble and distribute medical devices, surgical and diagnostic products and healthcare consumables.Bengaluru: Sandur Manganese & Iron Ores, the flagship company of the Karnataka-based Sandur Group, has incorporated a wholly owned subsidiary named Royal Sandur MedTech to take up the manufacture of medical devices and healthcare consumables, according to Business Standard.The certificate of incorporation for the new entity, a private limited company registered in India, was issued by the Ministry of Corporate Affairs on 25 September 2026, and the parent informed the stock exchanges of the...

The company is looking for a site of about 10,000 square metres and has opened talks with Invest UP, according to a company executive.Greater Noida: DNA Technology, a Russian maker of molecular diagnostic equipment and reagents, is in advanced talks to set up a manufacturing unit in Uttar Pradesh that would be its first production facility outside Russia, a company representative told Moneycontrol.Sergey Labutin, head of the company's international sales department, said on the sidelines of the Uttar Pradesh International Trade Show that the firm is searching for a site of around 10,000 square metres. That is roughly half the...

Imported first-aid kits meant only for workplace use in sectors such as automobiles and hospitality could skip import licensing if they carry at least 60% residual shelf life.New Delhi: The Drugs Technical Advisory Board (DTAB) has recommended relaxing sale and import licence requirements for a set of medical devices commonly used at home, including pulse oximeters, blood pressure monitors, thermometers, glucometers and urine pregnancy test kits, according to a report in Outlook India.The recommendations were made at the board's 94th meeting and cover products that consumers generally use directly or that serve limited, non-commercial purposes, the report said. Small quantities...

The brokerage set a target price of Rs 1,600, implying an upside of about 27 per cent over the stock's previous close of Rs 1,255.60. New Delhi: Shares of Molbio Diagnostics rose as much as 9 per cent on the National Stock Exchange on Wednesday after Jefferies began coverage of the point-of-care diagnostics maker with a buy rating, Business Standard reported. The stock touched an intraday high of Rs 1,369.20. By 9:40 am it had pared some of the gain and was trading 4.95 per cent higher at Rs 1,317.80, according to the report. Jefferies described Molbio as an innovation-led...

The drugmaker is expected to issue bonds with maturities of two, three and four years to replace part of a bridge loan of nearly $12 billion. Mumbai: Sun Pharmaceutical Industries is planning to raise about Rs 10,000 crore ($1.04 billion) through a sale of rupee-denominated bonds, using the money partly to take out a bridge loan it raised to acquire US healthcare company Organon & Co, Reuters reported on Tuesday, citing people familiar with the matter. The company, which is India's largest drugmaker by market capitalisation, will offer bonds of relatively short duration, with tenors of two, three and four...

The Malaysian hospital group also said it would fully cooperate with a forensic audit that the Supreme Court allowed to proceed last week. New Delhi: IHH Healthcare plans to lift its shareholding in Fortis Healthcare to 51 per cent over the next three to five years, the Malaysia-based company said in a stock exchange filing on Tuesday. IHH, which currently holds 31.17 per cent of Fortis, said it also intends to integrate its Fortis and Gleneagles platforms more closely and take its capacity to about 10,000 beds by 2031, according to the filing. "India remains a key strategic market for...

More than 24,000 families in the Ajnala constituency have already been issued health insurance cards under the scheme, the MLA said. Amritsar: Punjab's Mukh Mantri Sehat Bima Yojana will extend health insurance to 65 lakh families across the state, Aam Aadmi Party (AAP) spokesperson in Punjab and Ajnala MLA Kuldeep Singh Dhaliwal has said. He made the statement while addressing beneficiaries of the scheme, The Tribune reported on Wednesday. The state government had put its entire administrative machinery to work on preparing health insurance cards, Dhaliwal said at the event, describing the government's efforts on the exercise as determined, according...

The product allows reimbursement of medical costs without hospitalisation, a departure from insurance norms that generally tie a valid claim to a hospital stay. New Delhi: The Pension Fund Regulatory and Development Authority (PFRDA) is set to launch NPS Swasthya this week, a product that links retirement savings with healthcare spending and carries a standard super top-up health insurance cover, according to a Business Standard report. Finance Minister Nirmala Sitharaman is to inaugurate the scheme, the report said. According to the newspaper, NPS Swasthya brings together a set of products meant to ease access to healthcare services, so that subscribers...

Stakeholders can send comments on the distribution consultation paper until 25 October, after which draft regulations will go out for public consultation, Ajay Seth said. Mumbai: The Insurance Regulatory and Development Authority of India (Irdai) wants insurers to win customers on the price and quality of their products and services rather than on how much they can pay intermediaries, chairman Ajay Seth has said, adding that the proposed overhaul of distribution costs remains open to revision. He made the remarks in an interview with Business Standard published on Wednesday. Seth said the proposals draw on the objectives of the Sabka...

Once final approval comes through, the liquid anticoagulant will be made at Lupin's plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US Food and Drug Administration for its new drug application for apixaban oral suspension 1.25 mg/mL, the drugmaker said in a stock exchange filing on Monday. The application was filed through the 505(b)(2) pathway, according to the company. The product is a liquid version of apixaban, the active ingredient in Bristol Myers Squibb's blood thinner Eliquis. Apixaban is an oral anticoagulant used to prevent and treat blood clots and to lower...